A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia

Trial Profile

A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Aegerion Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 Results of an open-label extension study assessing additional long-term efficacy and safety of lomitapide along with results of an exploratory post hoc analysis assessing the potential metabolic consequences of hepatic fat accumulation, published in the Circulation Journal as a research letter.
    • 18 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top